DDX41: A unique player in myeloid leukemogenesis

FHS
July 20, 2024
2:24 am

A new editorial paper was published in Oncotarget’s Volume 15 on July 2, 2024, entitled, “DDX41 and its unique contribution to myeloid leukemogenesis.”

Syringe exchange fears hobble fight against West Virginia HIV outbreak

More than three years have passed since federal health officials arrived in central Appalachia to assess an alarming outbreak of HIV spread mostly between people

January 3, 2025

Selinexor by Karyopharm Therapeutics for Osteosarcoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

July 8, 2023

Impact of TKI Combinations in Front-Line Treatment of RCC

Updated results presented at the American Society of Clinical Oncology (ASCO) annual meeting involved frontline therapy in metastatic renal cell carcinoma (RCC), including the 5-year

July 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.